

## **Research Tool Disclosure Form**

By submitting this form, you agree to provide assistance to Cedars-Sinai's Technology Transfer Office efforts to commercialize the research tool disclosed herein. Your responsibilities may include providing technical input, complying with deadlines, and educating potential licensees about your research tool. Failure to respond to any official requests and/or deadlines may lead to the abandonment of any potential commercialization activity.

The level of detail you provide on this form will affect our ability to assess the strength of the research tool being submitted. If the provided space is insufficient, please attach a Word document. You may also attach any other documents related to the research tool.

## 1. Title of the Research Tool

		Percentage Contributed to Research Tool	Lead Contributor	
[Contributor Name, Degree (MD, PhD, etc.)]	[Department]	%		[Date]
[Contributor Name, Degree (MD, PhD, etc.)]	[Department]	%		[Date]
[Contributor Name, Degree (MD, PhD, etc.)]	[Department]	%		[Date]
[Contributor Name, Degree (MD, PhD, etc.)]	[Department]	%		[Date]
[Contributor Name, Degree (MD, PhD, etc.)]	[Department]	%		[Date]

To the best of your knowledge, in the space provided below, please list all funding sources used to develop the abovereferenced research tool to assist us in accurately reporting and identifying obligations. Please note that this section must be completed before we can start processing this disclosure.

Federal Funds	Non-federal	External Funds (CIRM, etc.)	Internal Funds	□ None
[Fund Agency]		[Grant No.]		
[Fund Agency]		[Grant No.]		
[Fund Agency]		[Grant No.]		

Research Tool Disclosure Form - Version: 09/2015

2.1. Research Tool Classification (Check all that apply)								
Antibody	Animal Model	Plasmid	Chemical Reagent					
□ Protein/Peptide	□ Cell Line	Viral Vector	Other (Describe below)					
Comments:	Comments:							
2.2. Application Areas (Check	c all that apply)	1	1					
	☐ GI Disorders	□ Nephrology	□ Radiation Control					
Drug Delivery	□ Health IT	Neurosciences	□ Research					
Drug Discovery/Screening	Imaging	Oncology	Stem Cells					
Endocrinology	Infectious Diseases	Organ Transplant	Surgery					
Gene Therapy	Inflammatory Disorder	Ortho/Spinal Disorders	Other (Describe below)					
Comments:		•	1					
2.3 Details (Please only com	plete relevant sections)							
Antibody   Monoclonal	Polyclonal							
🗆 Primary	□ Secondary							
Clone name:								
Immunogen:								
Specificity:								
Host species:								
Isotype:								
Purification method:								
Culture medium:								
Ascite production:								
Positive control:								
Applications:								
Amount available:								
Concentration:								
Conjugated (Yes/No):								
Other characteristics:								

Protein/Peptide
Name:
Origin species:
Sequence (please indicate protein tags or other modifications):
Molecular weight:
Concentration:
Form (liquid, powder, etc):
Purification method:
Purity:
Storage conditions:
Stability:
Other characteristics:
Animal Model
Name:
Species:
Background strain:
Targeted gene:
Genotype details (transgenic, targeted mutation, inducible):
Phenotype:
List any special housing requirements:
Breeding scheme used:
Are breeding pairs available?
Other characteristics:
Cell Line
Organism:
Tissue:
Product Format:
Morphology:
Culture Properties:
Storage Conditions:
Other characteristics:

Plasmid
Vector backbone:
Backbone size (bp):
Vector Type:
Gene/Insert name:
Cloning method (Restriction Enzymes):
Sequencing primers:
Bacterial Resistance(s):
Growth Temperature:
Growth strain(s):
Other characteristics:
Viral Vector
Target Gene:
Selection Marker:
Sequencing Primers:
Growth strain and conditions:
Storage Buffer:
Other characteristics:
Chemical Reagent
Please describe characteristics:
Other
Please describe characteristics:

3.	Description of the Research Tool		
a.	Describe the research tool, its key characteristics, and t	he amount	t available?
b.	What problem is addressed by this research tool? What	t is the pur	pose?
с.	Please list all publications describing validation, charact	teristics. an	d uses of the research tool.
	· · · · · · · · · · · · · · · · · · ·	,	
			- description - station - schetters - 2
a.	How does your research tool improve upon and provide	e a unique	advantage over existing solutions?
e.	Is this research tool derived from human tissue or same	oles? Please	e explain briefly.
f	Have you received any material transfer requests for th	nis research	tool:
	From colleagues within CSMC?	□ Yes	
	From any other academic/not for profit institutions?		
	From for-profit companies?	⊔ Yes	

## 4. Obligations to Third Parties

(Please reference below and attach documentation related to any external sponsorship, contracts, grants, materials, software, information or other funding associated to the creation of this research tool.)

a. Was this research tool developed at Cedars-Sinai? If "no", please explain.

b. The above-referenced research tool was developed in collaboration with a third party. 

Yes No

If yes, name of third party:\_\_\_\_

c. Third party material: Did you use any material or equipment provided by a third party to create this research tool?

If yes, please provide a list of all such materials (including related MTAs and any other related agreements) and their sources (Name of the PI and institution):

d. Briefly identify any other third party agreements or obligations (CDA, NDA, interinstitutional, service, consulting, collaboration, consortium, etc.).

## **5.** Business Development

**Please pay special attention to this section.** Your responses here are an important aspect of what we consider when strategizing optimal commercialization activity.

a. Describe how your research tool could be offered as a commercial product or service (i.e. reagent, diagnostic tool, kit, assay, or other).

b. Who could benefit from purchasing your research tool?

c. What specific companies may be interested in your research tool (development, production, sales, distribution, etc.)?

<b>6. Contributor Information</b> By signing this document you agree to follow the rules and regulations proposed by the Cedars-Sinai and the Technology Transfer Office for the creation, protection, and commercialization of research tools. If at any time your research plans change and you will no longer be working on this research tool, you agree to notify the Technology Transfer Office as soon as possible. Please check the box of the person who you designate as the primary contact. <i>Also, please make sure your Department Chairperson reviews the document and signs where applicable below.</i>						
Contributor #1 Primary contact						
Employed by CSMC?  Yes / No If "no", please name employer:						
Name:	Best reachable phone:	Best reachable email address:	Second best er	mail address:		
Best time to call:		Signature:		Date:		
Home Address:						
Country of Citizenship:						
Contributor #2 Primary contact	t 🗆					
Employed by CSMC?  Yes /	] No If "no", please name	employer:				
Name:	Best reachable phone:	Best reachable email address:	Second best e	mail address:		
Best time to call:		Signature:	-	Date:		
Home Address:						
Country of Citizenship:						
Contributor #3 Primary contact Employed by CSMC?  Yes /	t □ ]No If "no", please name	employer:				
Name:	Best reachable phone:	Best reachable email address:	Second best e	mail address:		
Best time to call:	l	Signature	1	Date:		
Home Address:						
Country of Citizenship:						
Contributor #4 Primary contact	t 🗆					
Employed by CSMC?  Yes /	] No If "no", please name	employer:				
Name:	Best reachable phone:	Best reachable email address:	Second best e	mail address:		
Best time to call:		Signature:	•	Date:		
Home Address:						
Country of Citizenship:						
Contributor #5 Primary contact						
Employed by CSMC?  Yes /	Employed by CSMC?  Yes / No If "no", please name employer:					
Name:	Best reachable phone:	Best reachable email address:	Second best e	mail address:		
Best time to call:		Signature:		Date:		

Home Address:						
Country of Citizenship:						
If the primary contact is out of reach for urgent matters, please contact:						
Is this individual a contributor?	🗆 Yes / 🗆 No					
Name:	Best reachable phone:	Best r	Best reachable email address: Second best e		mail address:	
Best time to call:		Signature:			Date:	
Home Address:						
Department Chair Approval (MANDATORY PER INSTITUTIONAL POLICY)						
Name:			Signature:			
Department:			Date:			

(Please include multiple copies of this page if more than five contributors will be specified)